Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics cash
Cash and short-term investments held at the end of each period.
Sarepta Therapeutics's cash was $878.78M at Sep 30, 2026. For fiscal 2025 it was $939.65M, down 31.4% from the year before. Over ten years it grew 16.5% a year on average. The highest annual figure on record is $2.13B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $939.65M | -31.4% |
| FY2024 | Dec 31, 2024 | $1.37B | -19.0% |
| FY2023 | Dec 31, 2023 | $1.69B | -15.8% |
| FY2022 | Dec 31, 2022 | $2.01B | -5.5% |
| FY2021 | Dec 31, 2021 | $2.13B | +9.1% |
| FY2020 | Dec 31, 2020 | $1.95B | +71.7% |
| FY2019 | Dec 31, 2019 | $1.13B | -3.4% |
| FY2018 | Dec 31, 2018 | $1.17B | +7.8% |
| FY2017 | Dec 31, 2017 | $1.09B | +231.0% |
| FY2016 | Dec 31, 2016 | $329.30M | +61.4% |
| FY2015 | Dec 31, 2015 | $204.00M | -3.4% |
| FY2014 | Dec 31, 2014 | $211.10M | -20.3% |
| FY2013 | Dec 31, 2013 | $264.90M | +41.2% |
| FY2012 | Dec 31, 2012 | $187.66M | +370.3% |
| FY2011 | Dec 31, 2011 | $39.90M | +18.8% |
| FY2010 | Dec 31, 2010 | $33.59M | -30.4% |
| FY2009 | Dec 31, 2009 | $48.28M | +331.3% |
| FY2008 | Dec 31, 2008 | $11.19M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $878.78M | +3.3% |
| Q2 FY2026 | Jun 30, 2026 | $788.49M | -1.5% |
| Q1 FY2026 | Mar 31, 2026 | $653.19M | +24.9% |
| Q4 FY2025 | Dec 31, 2025 | $939.65M | -31.4% |
| Q3 FY2025 | Sep 30, 2025 | $850.99M | -29.0% |
| Q2 FY2025 | Jun 30, 2025 | $800.14M | -45.2% |
| Q1 FY2025 | Mar 31, 2025 | $522.76M | -62.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.37B | -19.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.20B | -31.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.46B | -22.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.39B | -26.8% |
| Q4 FY2023 | Dec 31, 2023 | $1.69B | -15.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.75B | -16.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.88B | -3.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.90B | -6.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.01B | -5.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.09B | +30.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.95B | +12.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.02B | +15.8% |
| Q4 FY2021 | Dec 31, 2021 | $2.13B | +9.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.61B | -11.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.74B | -16.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.75B | -19.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.95B | +71.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.83B | +72.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.07B | +86.1% |
| Q1 FY2020 | Mar 31, 2020 | $2.18B | +61.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.13B | -3.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.06B | +33.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.11B | +17.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.35B | +28.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.17B | +7.8% |
| Q3 FY2018 | Sep 30, 2018 | $793.90M | +28.4% |
| Q2 FY2018 | Jun 30, 2018 | $950.20M | +214.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.05B | +168.4% |
| Q4 FY2017 | Dec 31, 2017 | $1.09B | +231.0% |
| Q3 FY2017 | Sep 30, 2017 | $618.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $301.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $391.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $329.30M | – |
See a number that looks wrong?